Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Arthritis, Rheumatoid 12Leukemia 5Spondylitis, Ankylosing 3Psoriasis 3Myelodysplastic Syndromes 3Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Arthritis, Psoriatic 2Spondylarthritis 1Respiratory Distress Syndrome 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Lung Neoplasms 1Lung Injury 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Bowel Diseases 1Infections 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1HIV Infections 1Gulf War Illness 1

Interventions

Cyclophosphamide 42fludarabine phosphate 33Peripheral Blood Stem Cell Transplantation 31Busulfan 31Tacrolimus 24Antilymphocyte Serum 24Cyclosporine 22Mycophenolic Acid 20Filgrastim 20Radiotherapy 19Methotrexate 19Melphalan 17Whole-Body Irradiation 13Methylprednisolone 12Etoposide 12Cord Blood Stem Cell Transplantation 11Cytarabine 9Sirolimus 7Flow Cytometry 7Azacitidine 7Alemtuzumab 7Specimen Handling 6Psychiatric Rehabilitation 6Cyclosporins 6Biopsy 6sargramostim 5ruxolitinib 5Thiotepa 5fludarabine 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Myelodysplastic-Myeloproliferative Diseases × Etanercept × Clear all
NCT00093366 2011-11-30

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 1/2 Completed
32 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00217386 2010-09-15

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 2 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡